含泰素的联合化疗治疗阿霉素耐药的转移性乳腺癌

Taxol containing Combination Regimen in Treatment of Adriamycin resistant Breast Cancer

１９９５年７月～１９９７年１２月，用含泰素的联合化疗方案治疗了阿霉素抗药的晚期乳腺癌２０例，其中ＥＴＰ方案治疗１２例，ＴＩＭ方案治疗４例，ＴＥ方案治疗２例，ＣＴＦ方案、ＴＩ方案治疗各１例。全组化疗共７４周期，中位周期数３．５周期（２～６周期）。结果，ＣＲ４例，ＰＲ１０例，ＭＲ２例，ＳＤ１例，ＰＤ３例，总有效率（ＣＲ＋ＰＲ）７０％。全组中位缓解期７个月（２～１３个月）。主要剂量限制毒性为骨髓抑制，以白细胞减少为主，Ⅲ度～Ⅳ度白细胞减少发生率为４３％。与泰素相关的常见不良反应为脱发、肌肉／关节痛和周围神经痛，发生率分别为１００％、８０％和４０％，均为轻、中度，停药后可恢复。我们认为含泰素的联合化疗对阿霉素耐药的转移性乳腺癌有很好的疗效。

From July 1995 to December 1997, 20 patients of adriamycin resistant breast cancer were treated with taxol containing combination.The taxol based regimens included ETP (etoposide/taxol/cisplatin) for 12 cases,TIM (taxol/ ifosfamide/mitoxantrone) for 2 cases. TE (taxol/epirubicine)for 2 cases,CTF (cyclophosphamide/taxol/5FU) and TI (taxol/ifosfamide) for 1 case each. A total of 74 cycles were administered with a median of 3.5 cycles per patient (range 2 6). The overall response rate was 70%. The median time of remission of responsers was 7 months (range 2 13). The main dose limiting toxicity was myelosuppression with grade III and IV neutropenia being in 43% and the other taxol related toxicities were alopecia (100%), myalgia/arthralgia (80%) and neurosensory (40%).Non hematologic toxicities were modest and recoverable on discontinuation of therapy. In conclusion, taxol containing combination regimen has significant antitumor activity in patients with adriamycin resistant metastatic breast cancer. It could be considered as a second line treatment regimen for refractory breast cancer. The adverse reactions were well tolerated by the majority of patients.